As the Q1 roller-coaster draws to a bumpy close, it’s time to move our attention to the coming quarter. Which are the key stocks out there right now to boost your portfolio’s second quarter returns? When the market is looking so volatile, you have to work a bit harder to find the best investing ideas.  Luckily we have TipRanks Analysts’ Top Stocks tool at our fingertips to provide some top-notch investing inspiration. This tool pinpoints stocks with multiple recent buy ratings from the Street’s best performing analysts. Here we used the following filters and ordered the results by upside potential.

As long as the stock hasn’t just recorded steep losses, the upside potential is a handy indicator of stocks that look undervalued right now and have big growth potential ahead. Plus all the stocks below have a ‘Strong Buy’ analyst consensus rating. So tick and tick! With that being said, let’s dive in and take a closer look at why these 5 stocks have such a bullish analyst rating right now:

1. TG Therapeutics, Inc. (TGTX)

Shares in TG Therapeutics have exploded by a whopping 76% so far in Q1. This innovative biotech is focused on developing novel treatments for devastating blood cancers and autoimmune diseases.

“We believe TG is generating a complete B-cell therapy franchise that is unique in the oncology space, which could provide substantial value across various B-cell cancers” writes B.Riley FBR’s Madhu Kumar. He selects TGTX as an Out the Gate 2018 Pick, due to his “reasonable confidence in success in the Phase III UNITY-CLL trial, with interim data expected in 2Q18.”

For investors looking for some serious upside potential, five-star HC Wainwright analyst Edward White sees the stock spiking to $38 (154% upside potential). He reiterated his buy rating on March 21. White bases his valuation on the potential revenue and success of the company’s two main drugs ublituximab and umbralisib. Combined, he is projecting 2026 revenue for these drugs of $990 million.